OLK Stock Overview
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OLK from our risk checks.
Olink Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.27 |
| 52 Week High | US$26.01 |
| 52 Week Low | US$14.10 |
| Beta | 0.50 |
| 1 Month Change | -7.78% |
| 3 Month Change | -11.03% |
| 1 Year Change | 2.96% |
| 3 Year Change | -41.99% |
| 5 Year Change | n/a |
| Change since IPO | -38.14% |
Recent News & Updates
Recent updates
Olink Holding AB (publ) (NASDAQ:OLK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 28
Is It Time To Consider Buying Olink Holding AB (publ) (NASDAQ:OLK)?
Oct 19We're Interested To See How Olink Holding (NASDAQ:OLK) Uses Its Cash Hoard To Grow
Jul 04A Look At The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Jun 13At US$21.02, Is It Time To Put Olink Holding AB (publ) (NASDAQ:OLK) On Your Watch List?
May 23Olink Holding (NASDAQ:OLK) Is In A Strong Position To Grow Its Business
Mar 20Calculating The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Dec 31Olink Holding partners with Discovery Life Sciences to establish commercial platform
Sep 20We're Hopeful That Olink Holding (NASDAQ:OLK) Will Use Its Cash Wisely
Sep 16Olink GAAP EPS of -$0.04, revenue of $27.5M; reaffirms FY22 guidance
Aug 11We're Not Very Worried About Olink Holding's (NASDAQ:OLK) Cash Burn Rate
May 16Olink Holding Plans Strong 2022 Spending Amid Growth Slowdown
May 13Olink Holding AB (publ) (NASDAQ:OLK) Just Reported, And Analysts Assigned A US$29.75 Price Target
Feb 17Companies Like Olink Holding (NASDAQ:OLK) Can Afford To Invest In Growth
Jun 25Shareholder Returns
| OLK | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -3.3% | -5.9% | -3.7% |
| 1Y | 3.0% | -5.5% | 20.2% |
Return vs Industry: OLK exceeded the US Life Sciences industry which returned -4.3% over the past year.
Return vs Market: OLK underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| OLK volatility | |
|---|---|
| OLK Average Weekly Movement | 3.0% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OLK has not had significant price volatility in the past 3 months.
Volatility Over Time: OLK's weekly volatility has decreased from 11% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 707 | Jon Heimer | www.olink.com |
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company’s products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services.
Olink Holding AB (publ) Fundamentals Summary
| OLK fundamental statistics | |
|---|---|
| Market cap | US$2.77b |
| Earnings (TTM) | -US$31.60m |
| Revenue (TTM) | US$169.60m |
16.3x
P/S Ratio-87.6x
P/E RatioIs OLK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OLK income statement (TTM) | |
|---|---|
| Revenue | US$169.60m |
| Cost of Revenue | US$55.14m |
| Gross Profit | US$114.46m |
| Other Expenses | US$146.06m |
| Earnings | -US$31.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 67.49% |
| Net Profit Margin | -18.63% |
| Debt/Equity Ratio | 0% |
How did OLK perform over the long term?
See historical performance and comparison